Modern View on the Etiology and Pathogenesis of Endocrine Ophthalmopathy
https://doi.org/10.51523/2708-6011.2019-16-1-2
Abstract
Endocrine ophthalmopathy (EOP) is an autoimmune progressing pathology, which in most cases is associated with Graves’ disease (GD), but also occurs in patients with autoimmune thyroiditis and euthyroidism without symptoms of thyroid disease. Despite the existence of the proven interconnection between thyroid pathology and EOP, the mechanisms of its pathogenesis have not been studied completely. The article covers the modern theories of etiology and pathogenesis, genetic predisposition to the development of EOP, the risk factors, features of the clinical course and major complications of this pathology. EOP may cause significant loss of visual acuity and lead to disability, so only the multidisciplinary approach, timely diagnosis and treatment may prevent the complications and preserve the quality of life of patients.
About the Authors
O. P. Sadovskaya
Учреждение образования «Гомельский государственный медицинский университет»
Belarus
Belarus
L. V. Dravitsa
Учреждение образования «Гомельский государственный медицинский университет»
Belarus
Belarus
References
1. Maheshwari R, Weis E. Thyroid Associated Orbitopathy. Indian J of Ophthalmology. 2012;60:87-93.doi: 10.4103/0301-4738.94048.
2. Carballo MCS, de Sá BPC, Rocha DRTW, Arbex AK. (2017) Pathophysiology of Graves’ Ophthalmopathy: A Literature Review. Open J of Endocrine and Metabolic Diseases. 2017;7(1):77-87. doi: 10.4236/ojemd.2017.71008.
3. Gleeson H, Kelly W, Toft A, Dickinson J, Kendall TP. Severe thyroid eye disease associated with primary hypothyroidism and thyroid-associated dermopathy. Thyroid. 1999; 9(11):1115-1118.doi: 10.1089/thy.1999.9.1115.
4. Burch HB, Wartofsky L. Graves’ Ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993; 14:747-793. doi: 10.1210/edrv-14-6-747.
5. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: Reality and perspectives. Endocr Rev.2000;21:168-99. doi: 10.1210/edrv.21.2.0393.
6. Tellez M, Cooper J, Edmonds C. Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf).1992;36:291-4.
7. Brovkina AF. `Endokrinnaj aoftalmopatija. Moskva, RF: GEOTAR-MED; 2004. 176 р. (in Russ.)
8. Likhvantseva VG., Korosteleva EV, Kovelenova IV., Budanov SV, Ben Rezh Amin. Deficit glaznogo krovotoka - klyuchevoj faktor, opredelyayushchij formu vtorichnoj glaukomy pri ehndokrinnoj oftal'mopatii. Rus Ophthalmological Journ. 2016; 9(3):43-49. doi: 10.1016/0014-4835(92)90793-r. (in Russ.)
9. Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR. Risk Factors and Clinical Characteristics of GO. J Clin Endocrinol Metab. 2016;101(7):2711-2720. doi: 10.1210/jc.2015-4294.
10. Wiersinga WM, Kahaly GJ, editors. Graves’ Orbitopathy: A Multidisciplinary Approach: questions and answers. 2nd ed. Basel, Switzerland: Karger; 2007. 285 p.
11. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002;12:855-860. doi: 10.1089/105072502761016476.
12. Sviridenko NYu, Lihvanceva VG, Belovalova IM, SHeremeta MS, Tabeeva KI. Antitela k receptoru TTG kak prediktory tyazhestii iskhodov ehndokrinnoj oftal'mopatii u pacientov s bolezn'yu Grejvsa. Probl Ehndokrinologii. 2011;2:23-26. (in Russ.)
13. Carballo MCS, de Sa BPC, Rocha DRTW, Arbex AK. Pathophysiology of Graves’Ophthalmopathy: A Literature Review. Open J of Endocrine and Metabolic Diseases. 2017;7:77-87. doi: 10.4236/ojemd.2017.71008.
14. Stan MN, Bahn RS. Risk Factors for Development or Deterioration of Graves’ Ophthalmophaty. Thyroid. 2010;20:777-783. doi: 10.1089/thy.
15. Harincev VV, Serkin DM, Serebryakova OV, Harinceva SV. Znachenie nekotoryh rostovyh faktorov v patogeneze ehndokrinnoj oftal'mopatii. Klin i Ehksperimental'naya Tireoidologiya. 2017;3(1):12-19. doi: 10.14341/ket2017112-19. (in Russ.)
16. Lihvanceva VG, Kuz'min VA, Korostelyova VE, Solomatina MV, Budanova SV. Poisk i identifikaciya receptorov tireoidnyh gormonov v tkanyah glaza. Oftal'mologiya. 2014;11(2):27-30. doi: 10.18008/1816-5095-2014-4. (in Russ.)
17. Şahlı E. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol. 2017;47:94-105. doi: 10.4274/tjo.80688.
18. Likhvantseva VG, Kharlap SI, Korosteleva EV, et al. Contribution of hemodynamic disturbances in magistral vessels to optic neuropathy progression and ocular tension changes in endocrine ophthalmopathy. Annals of Ophthalmology. 2015;131(4):32-37. (in Russ.)
19. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy for Graves’ disease and the effect on ophthalmopathy-a systematic review. Clin Endocrinol (Oxf). 2008;69:943-950 doi: 10.1111/j.1365-2265.2008.03279.x.
20. Saakyan SV, Panteleeva OG, Sirmajs OS. Osobennosti klinicheskogo techeniya ehndokrinnoj oftal'mopatii v detskom vozraste. Ros Pediatr Oftal'mologiya. 2014;3:20-23. (in Russ.)
Review
For citations:
Sadovskaya O.P., Dravitsa L.V. Modern View on the Etiology and Pathogenesis of Endocrine Ophthalmopathy. Health and Ecology Issues. 2019;(1):9-14. (In Russ.) https://doi.org/10.51523/2708-6011.2019-16-1-2
Views: 446
Email this article 